Kowentush Medlabs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 M
- Revenue Growth 16.42%
- Profit Growth 19.58%
- Ebitda 60.50%
- Net Worth 35.36%
- Total Assets 17.29%
About Kowentush Medlabs
Kowentush Medlabs Private Limited (KMPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2017 (Seven years and five months 19 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.00 M.
Rajnish Kumar and Swarnlata Devi serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304BR2017PTC035645
- Company No.
035645
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Kowentush Medlabs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnish Kumar  | Director | 07-Sep-2017 | Current |
| Swarnlata Devi | Director | 07-Sep-2017 | Current |
Financial Performance of Kowentush Medlabs.
Kowentush Medlabs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 16.42% increase. The company also saw a substantial improvement in profitability, with a 19.58% increase in profit. The company's net worth Soared by an impressive increase of 35.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kowentush Medlabs?
In 2020, Kowentush Medlabs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
R.K. Sales Private LimitedRajnish Kumar is a mutual person
Charges (Loans)
₹6.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.49 Cr
- Indian Bank : 0.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Oct 2022 | Indian Bank | ₹1.10 M | Open |
| 06 Feb 2019 | Others | ₹4.90 M | Open |
How Many Employees Work at Kowentush Medlabs?
Unlock and access historical data on people associated with Kowentush Medlabs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kowentush Medlabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kowentush Medlabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
